Details for: INFLECTRA
Company: CELLTRION HEALTHCARE CO LTD
| DIN | DIN name | Active Ingredient(s) | Strength | Dosage Form | Route of Administration |
|---|---|---|---|---|---|
| 02419475 | INFLECTRA | INFLIXIMAB | 100 MG / VIAL | POWDER FOR SOLUTION | INTRAVENOUS |
Summary Reports
Summary Basis of Decision
Regulatory Decision Summary
Regulatory Decision Summary
Summary Safety Review - REMICADE (infliximab) - Evaluating for the Risk of Cancer (Lymphoma, Hepatosplenic T-Cell Lymphoma, and Leukemia)
Summary Safety Review - Tumour necrosis factor (TNF) blockers - Glioblastoma (brain tumour)
Regulatory Decision Summary
Regulatory Decision Summary
Summary Safety Review - REMICADE (infliximab) - Evaluating for the Risk of Cancer (Lymphoma, Hepatosplenic T-Cell Lymphoma, and Leukemia)
Summary Safety Review - Tumour necrosis factor (TNF) blockers - Glioblastoma (brain tumour)
Consumer Information
The Consumer Information is not yet available in the Drug and Health Product Register. Try searching on the active ingredient(s) to find other similar products.